Emerging hERG services Creative Bioarray recently launched a flagship hERG safety assay service, signaling an opportunity to cross-sell expanded cardiotoxicity screening capabilities to drug discovery teams seeking safer compound profiling.

Epigenetic and iPSC expansion With new epigenetic induction services for cell immortalization and expanded iPSC differentiation and characterization offerings, there is potential to pitch end-to-end stem cell research solutions to biotech firms advancing cell therapies and regenerative medicine programs.

GMP-grade cytokines Availability of GMP-grade cytokines supports cell manufacturing and therapeutic development, presenting a clear sales path to customers building GMP-compliant production pipelines and outsourced manufacturing partnerships.

Tissue and reference materials As the first commercial entity focused on a large tissue-sharing platform with rich clinical data, Creative Bioarray can be positioned as a strategic partner for labs needing standardized reference materials and associated data services to de-risk preclinical studies.

Compact agile partner Small team size combined with a broad service expansion cadence suggests an attractive target for mid-market biotech startups and CROs seeking flexible, responsive collaboration on inflammation, angiogenesis, apoptosis, and signal transduction assay work.